Exploiting the CXCR4-CD44 axis for cancer treatment

In order to contribute to developing innovative and complementary approaches to fight against cancer, the partners aim at understanding how CXCR4 signalling complexes form and how this impacts cytotoxic lymphocytes (CTL) behaviour by using proteomics, in vivo targeting and computational modelling. As CXCR4 plays an important role in CTL reactivation, more insight about its regulation in space and time may provide novel information with therapeutic potential for improving immune checkpoint therapy (ICT). The project is supported by Eucor – The European Campus in the “Research and Innovation” category of the Seed Money scheme.

Read the article of the University of Strasbourg on this project (French).

This project is now closed. You can find out more about its implementation here: